Enlivex Immunotherapy Company raises $21 million through a debt agreement to expand its crypto asset accumulation strategy, focusing on the RAIN token of the Rain prediction platform. The company spent $10 million to purchase an additional 3 billion RAIN tokens at a 62% discount, while also extending the option to buy an additional 272.1 billion tokens until December 2027. The funds come from asset management firm The Lind Partners.
Meanwhile, Enlivex also approved a $20 million share buyback program to increase shareholder value. Rain’s model incorporates a 2.5% fee mechanism used for token buybacks and burns, supporting supply and demand incentives.
Following this news, RAIN slightly increased to $0.009 before adjusting, while ENVL shares showed no significant movement. Investment trends in the prediction market are surging, with industry-wide trading volume increasing over 1,200% in a year.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
